Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Chemotherapy in Resectable Recurrent Head and Neck Squamous Cell Carcinoma
NCT05726370Phase 2Recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- May 2023
- Primary completion
- Dec 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in head and neck squamous cell carcinoma (HNSCC), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Major Pathological Response at 2 months. Started May 2023; status: recruiting.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT05726370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05726370.